Mithun Maity

Sir, my question with regards to the Sanofi acquisition, which is more on asset -light model as we are not acquiring any of their assets, manufacturing assets. Since there are no factories being acquired, the Sanofi's portfolio molecule will be manufactured immediately by whom as in post- closing this deal as and when it will be manufactured.

Yes, after the post-closing the deal.

So after 3 years, this would be completely manufactured by us. That's the plan, right?